menu
    • menu
    [{"orgOrder":0,"company":"BioAxone BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"BA-1049","moa":"Rho-associated protein kinase 2","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"BioAxone BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioAxone BioSciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"BioAxone BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"BioAxone BioSciences","sponsor":"Neurelis","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"BA-1049","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"BioAxone BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioAxone BioSciences \/ Neurelis","highestDevelopmentStatusID":"4","companyTruncated":"BioAxone BioSciences \/ Neurelis"}]

    Find Clinical Drug Pipeline Developments & Deals for BA-1049

    Menu

    BA-1049

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BioAxone BioSciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            BioAxone BioSciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BA-1049

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Neurelis

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Neurelis Announces Acquisition Of Rights To Portfolio Of NCE Compounds

                            Details : Neurelis intends to submit an Investigational New Drug (IND) application with the FDA on BioAxone's lead compound, BA-1049, in 2022. BioAxone's lead product, BA-1049, offers an opportunity to treat CCMs by stabilizing lesions and by preventing new lesio...

                            Brand Name : BA-1049

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 21, 2021

                            Lead Product(s) : BA-1049

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Neurelis

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BioAxone BioSciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            BioAxone BioSciences

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BA-1049

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BioAxone BioSciences Announces Notice of Allowance that Expands Scope of Key ROCK Inhibitors for Treatment of ...

                            Details : The latest notice covers the critical patent application (US 16/214,973) for the proprietary method of treatment of cerebral aneurysms with BA-1049 and other ROCK2 oral drug candidates now in development.

                            Brand Name : BA-1049

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 28, 2020

                            Lead Product(s) : BA-1049

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth